Ardelyx, Inc. ARDX
Ardelyx, Inc. (Nasdaq: ARDX) is a GI/hepatology drug developer. Its lead program, tenapanor (IBSRELA) in chronic idiopathic constipation (ACCEL), is in Phase 3 for chronic idiopathic constipation (CIC). Its next catalyst on record is tenapanor CIC (ACCEL): Complete enrollment in Phase 3 ACCEL (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tenapanor CIC (ACCEL) — Complete enrollment in Phase 3 ACCEL (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tenapanor (IBSRELA) | IBS-C (approved, adults) | small molecule | Approved |
| tenapanor (XPHOZAH) | hyperphosphatemia in CKD on dialysis (approved) | small molecule | Approved |
| tenapanor (IBSRELA) ACCEL Phase 3 | chronic idiopathic constipation | small molecule | Phase 3 |
| tenapanor (IBSRELA) pediatric trials | pediatric IBS-C | small molecule | Phase 2 |
| RDX10531 | next-generation NHE3 inhibitor, multiple areas | small molecule | Pre-clinical |
Recent results and decisions
- Feb 19, 2026started Phase 3 ACCEL trial of tenapanor (IBSRELA) in chronic idiopathic constipation launched, first patient dosed in Q1 2026.
has launched a Phase 3 trial, ACCEL, to assess tenapanor in patients with CIC, dosing the first patient in Q1 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.